Completed PHASE4 INTERVENTIONAL NCT00044720

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Chronic Kidney Failure Graft vs Host Disease Kidney Transplantation

Interventions Rapamune

Updated 5 times since 2017 Last updated: Aug 17, 2009 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00044720, this PHASE4 trial focuses on Chronic Kidney Failure and Graft vs Host Disease and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.